Matching articles for "ondansetron"
Issue 1721 · February 3, 2025
Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)

View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):e1 doi:10.58347/tml.2025.1721c
View Figure: Treatments for Irritable Bowel Syndrome (IBS) in Adults
Issue 1721 · February 3, 2025
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom:…

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):17-24 doi:10.58347/tml.2025.1721a
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Issue 1721 · February 3, 2025
Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)

View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):e1-2 doi:10.58347/tml.2025.1721b
View the Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation
Issue 1721 · February 3, 2025
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)

View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)

Med Lett Drugs Ther. 2025 Feb 3; 67(1721):e1-3 doi:10.58347/tml.2025.1721f
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Issue 1618 · February 22, 2021
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by…

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):25-32
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Issue 1618 · February 22, 2021
Comparison Table: Drugs for Parkinson's Disease (online only)

View the Comparison Table: Drugs for Parkinson's Disease

Med Lett Drugs Ther. 2021 Feb 22; 63(1618):e1-9
View the Comparison Table: Drugs for Parkinson's Disease
Issue 1615 · January 11, 2021
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis

The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D 2 ) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis.…

Med Lett Drugs Ther. 2021 Jan 11; 63(1615):5-7
The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D 2 ) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide ( Reglan , and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis.
Issue 1614 · December 28, 2020
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults.…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):205-8
The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Issue 1594 · March 23, 2020
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel…

Med Lett Drugs Ther. 2020 Mar 23; 62(1594):41-8
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Issue 1594 · March 23, 2020
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)

View the Table: Safety of Drugs for IBS in Pregnancy and Lactation

Med Lett Drugs Ther. 2020 Mar 23; 62(1594):e48-9
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Issue 1523 · June 19, 2017
Obalon Balloon System - Another Gastric Balloon for Weight Loss

The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40 kg/m 2 who have not been…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):102-3
The FDA has approved the Obalon Balloon System (Obalon), a swallowable intragastric gas-filled balloon device, to facilitate weight loss in adults with a body mass index (BMI) of 30-40 kg/m 2 who have not been able to lose weight through diet and exercise. Two other gastric balloon devices, ReShape and Orbera , were approved earlier.
Issue 1504 · September 26, 2016
Drugs for Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as…

Med Lett Drugs Ther. 2016 Sep 26; 58(1504):121-6
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Issue 1487 · February 1, 2016
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer…

Med Lett Drugs Ther. 2016 Feb 1; 58(1487):17-8
The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT 3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Issue 1467 · April 27, 2015
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):61-3
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) was the first.
Issue 135 · November 1, 2013
Drugs for Parkinson's Disease

The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused…

Treat Guidel Med Lett. 2013 Nov; 11(135):101-6
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Issue 1406 · December 24, 2012 Free
In Brief: Intravenous Ondansetron (Zofran) 32 mg Withdrawn

The FDA has announced that the single 32-mg IV dose of ondansetron ( Zofran , and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because…

Med Lett Drugs Ther. 2012 Dec 24; 54(1406):104
The FDA has announced that the single 32-mg IV dose of ondansetron ( Zofran , and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it can prolong the QT interval and could possibly cause a torsades de pointes cardiac arrhythmia. For this indication, the only recommended dose of IV ondansetron is 0.15 mg/kg (maximum 16 mg/dose) every 4 hours for 3 doses. There are no changes in the recommended dosing regimens for oral ondansetron or for IV ondansetron used for prevention of postoperative nausea and vomiting. Download complete U.S. English article
Issue 101 · January 1, 2011
Drugs for Parkinson's Disease

Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the…

Treat Guidel Med Lett. 2011 Jan; 9(101):1-6
Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the blood-brain barrier.
Issue 1330 · January 25, 2010
Medical Marijuana

Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):5-6
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa) . In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1301 · December 15, 2008
A Granisetron Patch (Sancuso)

The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):103-0
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation ( Sancuso - ProStrakan).
Issue 62 · October 1, 2007
Drugs for Parkinson's Disease

ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the…

Treat Guidel Med Lett. 2007 Oct; 5(62):89-94
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Issue 1200 · January 17, 2005
Apomorphine (Apokyn) for Parkinson's Disease

Apomorphine ( Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with…

Med Lett Drugs Ther. 2005 Jan 17; 47(1200):7-8
Apomorphine ( Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been available in Europe for many years.
Issue 1179 · March 29, 2004
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved…

Med Lett Drugs Ther. 2004 Mar 29; 46(1179):27-8
Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin ( Platinol , and others). Aprepitant ( Emend ), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT 3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs ( Medical Letter 2003; 45:62 ).
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1026 · May 8, 1998
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Dolasetron ( Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT 3 ) receptor antagonist similar to ondansetron (Zofran) and granisetron ( Kytril - Medical Letter, 36:61, 1994) is now available for…

Med Lett Drugs Ther. 1998 May 8; 40(1026):53-4
Dolasetron ( Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT 3 ) receptor antagonist similar to ondansetron (Zofran) and granisetron ( Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT 3 antagonist plus dexamethasone ( Decadron , and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and vomiting.
Issue 926 · July 8, 1994
Granisetron to Prevent Vomiting After Cancer Chemotherapy

Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although…

Med Lett Drugs Ther. 1994 Jul 8; 36(926):61-2
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although available in an oral formulation in other countries, granisetron is available here only for intravenous (IV) use.
Issue 912 · December 24, 1993
Drugs for Vomiting Caused by Cancer Chemotherapy

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24; 35(912):124-6
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Issue 847 · June 28, 1991
Ondansentron To Prevent Vomiting After Cancer Chemotherapy

Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An…

Med Lett Drugs Ther. 1991 Jun 28; 33(847):63-4
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.